Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H26O2 |
| Molecular Weight | 274.3985 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@]12CC[C@]3([H])[C@@]4([H])CCC(=O)C=C4CC[C@@]3([H])[C@]2([H])CC[C@]1([H])O
InChI
InChIKey=NPAGDVCDWIYMMC-IZPLOLCNSA-N
InChI=1S/C18H26O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,13-17,20H,2-9H2,1H3/t13-,14+,15+,16-,17-,18-/m0/s1
DescriptionCurator's Comment:: Description was created based on several sources, including
https://empower.pharmacy/drugs/nandrolone-decanoate-injection.html
https://us.basicstero.info/nandrolones
Curator's Comment:: Description was created based on several sources, including
https://empower.pharmacy/drugs/nandrolone-decanoate-injection.html
https://us.basicstero.info/nandrolones
Nandrolone, also known as 19-nortestosterone or 19-norandrostenolone, is a semisynthetic anabolic-androgenic steroid derived from testosterone. Nandrolone is used in the form of a variety of long-acting prodrug esters for intramuscular injection, the most common of which are nandrolone decanoate. Nandrolone decanoate is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. Certain clinical effects and adverse reactions demonstrate the androgenic properties of this class of drugs. Complete dissociation of anabolic and androgenic effects has not been achieved. The actions of anabolic steroids are therefore similar to those of male sex hormones with the possibility of causing serious disturbances of growth and sexual development if given to young children. Anabolic steroids suppress the gonadotropic functions of the pituitary and may exert a direct effect upon the testis. Anabolic steroids have been reported to increase low-density lipoproteins and decrease high-density lipoproteins. Synthetic version of nandrolone was developed in 1950. But nandrolone for sale appeared later only in 1962 in the form of decanoate under the trade name Deca-Durabolin (Organon company).
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P10275 Gene ID: 367.0 Gene Symbol: AR Target Organism: Homo sapiens (Human) |
|||
Target ID: CHEMBL1871 |
|||
Target ID: P10275 Gene ID: 367.0 Gene Symbol: AR Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | NANDROLONE DECANOATE Approved UseNandrolone decanoate is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. Surgically induced anephric patients have been reported to be less responsive. Launch Date1.28312646E12 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
36.1 μg/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10435281 |
6 mL single, oral dose: 6 mL route of administration: Oral experiment type: SINGLE co-administered: |
NANDROLONE PHENPROPIONATE blood | Sus scrofa population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
219.9 μg × h/L EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/10435281 |
6 mL single, oral dose: 6 mL route of administration: Oral experiment type: SINGLE co-administered: |
NANDROLONE PHENPROPIONATE blood | Sus scrofa population: HEALTHY age: UNKNOWN sex: FEMALE / MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Sport nutritional supplements: quality and doping controls. | 2001 |
|
| Advances in male hormonal contraception. | 2001 Dec |
|
| Climodien (estradiol valerate 2 mg plus dienogest 2 mg) is safe and effective in the treatment of postmenopausal complaints. | 2001 Dec |
|
| Effect of nandrolone decanoate on the lipid profile of male peritoneal dialysis patients. | 2001 Nov-Dec |
|
| [Urinary nandrolone metabolites in antidoping control]. | 2001 Sep |
|
| Effect of combined treatment with nandrolone and cocaine on the NMDA receptor gene expression in the rat nucleus accumbens and periaqueductal gray. | 2002 |
|
| Estradiol valerate/dienogest. | 2002 |
|
| Role of androgens in female genital sexual arousal: receptor expression, structure, and function. | 2002 Apr |
|
| Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. | 2002 Apr |
|
| Randomized prospective comparison between erythropoietin and androgens in CAPD patients. | 2002 Apr |
|
| Aromatase and breast cancer: W39R, an inactive protein. | 2002 Apr |
|
| Effects of withdrawal from anabolic androgenic steroids on aggression in adult male rats. | 2002 Apr 1 |
|
| The popliteal-artery entrapment syndrome in a patient using anabolic steroids. | 2002 Apr 18 |
|
| In situ detection and quantification of bursa of fabricius cellular proliferation or apoptosis in normal or steroid-treated neonatal chicks. | 2002 Aug |
|
| Molecular imprinted polymer coated QCM for the detection of nandrolone. | 2002 Aug |
|
| Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. | 2002 Aug |
|
| Treatment of menstruation-associated recurrence of hereditary pancreatitis with pharmacologic ovarian suppression. | 2002 Aug 1 |
|
| The F-box protein SKP2 mediates androgen control of p27 stability in LNCaP human prostate cancer cells. | 2002 Aug 20 |
|
| Lack of stimulatory effect of dienogest on the expression of intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 by endothelial cell as compared with other synthetic progestins. | 2002 Aug 30 |
|
| Nandrolone: generic now in stock. | 2002 Aug 9 |
|
| Metabolic effects of nandrolone decanoate and resistance training in men with HIV. | 2002 Dec |
|
| The anabolic androgenic steroid, nandrolone decanoate, increases the density of Fos-like immunoreactive neurons in limbic regions of guinea-pig brain. | 2002 Feb |
|
| Physical provocation potentiates aggression in male rats receiving anabolic androgenic steroids. | 2002 Feb |
|
| Abuse of performance-enhancing drugs in sport. | 2002 Feb |
|
| Role of IGF-I and IGF-binding proteins within diaphragm muscle in modulating the effects of nandrolone. | 2002 Feb |
|
| Hair analysis of seven bodybuilders for anabolic steroids, ephedrine, and clenbuterol. | 2002 Jan |
|
| Misuse of androgenic-anabolic steroids and human deltoid muscle fibers: differences between polydrug regimens and single drug administration. | 2002 Jan |
|
| Inhibition of oestrone sulphatase activity by tibolone and its metabolites. | 2002 Jan |
|
| Human nutritional supplements in the horse: comparative effects of 19-norandrostenedione and 19-norandrostenediol on the 19-norsteroid profile and consequences for doping control. | 2002 Jan 25 |
|
| Endogenous nandrolone metabolites in human urine. Two-year monitoring of male professional soccer players. | 2002 Jan-Feb |
|
| The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. | 2002 Jul |
|
| Nandrolone decanoate treatment induces changes in contractile responses of rat untrained fast-twitch skeletal muscle. | 2002 Jul |
|
| Steroid receptor concentration in aged rat hindlimb muscle: effect of anabolic steroid administration. | 2002 Jul |
|
| Treatment for HIV wasting withdrawn. | 2002 Jun |
|
| Anabolic androgenic steroid affects competitive behaviour, behavioural response to ethanol and brain serotonin levels. | 2002 Jun 15 |
|
| Nandrolone (Deca Durabolin) disappears in U.S., generic may return in July. | 2002 Jun 28 |
|
| Effect of dienogest-containing oral contraceptives on lipid metabolism. | 2002 Mar |
|
| Characterization of bone mineral composition in the proximal tibia of cynomolgus monkeys: effect of ovariectomy and nandrolone decanoate treatment. | 2002 Mar |
|
| The human ovarian surface epithelium is an androgen responsive tissue. | 2002 Mar 18 |
|
| Enzyme-assisted synthesis and structure characterization of glucuronide conjugates of methyltestosterone (17 alpha-methylandrost-4-en-17 beta-ol-3-one) and nandrolone (estr-4-en-17 beta-ol-3-one) metabolites. | 2002 Mar-Apr |
|
| Anti-androgenic and hair growth promoting activities of Lygodii spora (spore of Lygodium japonicum) I. Active constituents inhibiting testosterone 5alpha-reductase. | 2002 May |
|
| Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men. | 2002 May |
|
| Evaluation of human hepatocyte incubation as a new tool for metabolism study of androstenedione and norandrostenedione in a doping control perspective. | 2002 Nov 15 |
|
| Urine nandrolone metabolites: false positive doping test? | 2002 Oct |
|
| Synthesis of nitrile derivatives of estrogens. | 2002 Oct 21 |
|
| Impact of hormone replacement therapy on endogenous estradiol metabolism in postmenopausal women. | 2002 Oct 25 |
|
| Repeated anabolic-androgenic steroid treatment during adolescence increases vasopressin V(1A) receptor binding in Syrian hamsters: correlation with offensive aggression. | 2002 Sep |
|
| Successful DNA typing of a urine sample in a doping control case using human mitochondrial DNA analysis. | 2002 Sep |
|
| Effects of adjuvant androgen on anemia and nutritional parameters in chronic hemodialysis patients using low-dose recombinant human erythropoietin. | 2002 Sep |
|
| Nandrolone excretion is not increased by exhaustive exercise in trained athletes. | 2002 Sep |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QA14AB01
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
LIVERTOX |
667
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
NDF-RT |
N0000175824
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
NCI_THESAURUS |
C243
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
DEA NO. |
4000
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
WHO-ATC |
A14AB01
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
NCI_THESAURUS |
C2360
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
FDA ORPHAN DRUG |
712219
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
WHO-ATC |
S01XA11
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
||
|
WHO-VATC |
QS01XA11
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6PG9VR430D
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
D009277
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
1879
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
3368
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
NANDROLONE
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
7244
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | RxNorm | ||
|
DB00984
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
434-22-0
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
207-101-0
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
C29279
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
6949
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
1454008
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | USP-RS | ||
|
9904
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
295
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
434-22-0
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
M7720
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | Merck Index | ||
|
CHEMBL2104906
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY | |||
|
SUB09148MIG
Created by
admin on Sat Jun 26 07:14:24 UTC 2021 , Edited by admin on Sat Jun 26 07:14:24 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE LESS ACTIVE (PARENT)
